:: Library Catalog

Copertina

Salvato in:

Dettagli Bibliografici
Autori principali:	Joao Paulo B. Ximenez, Jurandyr Moreira de Andrade, Adriana Rocha, Eduardo Barbosa Coelho, Guilherme Suarez‐Kurtz, Vera Lucia Lanchote
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Clinical and Translational Science
Accesso online:	https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.13713
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

From Genotype to Therapeutic Monitoring: Enhancing Tamoxifen Efficacy in Breast Cancer Treatment
di: Ana Flávia Mendes Batista, et al.
Pubblicazione: (2025)

A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib
di: Amanda Long, et al.
Pubblicazione: (2024)

Targeting lysine methyltransferase 2C deficiency: New frontiers in breast cancer therapy and prognosis
di: Shuangmei Tong, et al.
Pubblicazione: (2026)

Is there a possibility that P‐glycoprotein reduces reproductive toxicity in males but breast cancer resistance protein does not?
di: Zhiheng Yu, et al.
Pubblicazione: (2024)

Stimulator of interferon genes (STING)‐activating nanomedicines: Translating innate immune modulation into effective therapy for triple‐negative breast cancer
di: Harshita Singhai, et al.
Pubblicazione: (2026)

Targeting biomolecular condensates to inhibit breast cancer
di: Xiaoxue Zhou, et al.
Pubblicazione: (2025)

Nanomedicine: a frontier of the breast cancer treatment
di: Swarup Sonar, et al.
Pubblicazione: (2024)

Matrix metalloproteinase 2‐responsive dual‐drug‐loaded self‐assembling peptides suppress tumor growth and enhance breast cancer therapy
di: Jihong Ma, et al.
Pubblicazione: (2024)

Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A /P‐gp Modulators
di: Akiko Watanabe, et al.
Pubblicazione: (2025)

Seize the engine: Emerging cell cycle targets in breast cancer
di: Jesús Fuentes‐Antrás, et al.
Pubblicazione: (2024)

Towards a quantum therapy in cancer
di: Frankie James Rawson
Pubblicazione: (2025)

Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data
di: Bianca Kruger, et al.
Pubblicazione: (2024)

Dynamics of the intratumoural microbiome across malignant transformation and treatment in breast cancer
di: Liuliu Quan, et al.
Pubblicazione: (2025)

Pharmaceutical company payments to Japanese breast cancer practice guideline authors
di: Anju Murayama, et al.
Pubblicazione: (2024)

Single‐cell transcriptional atlas of human breast cancers and model systems
di: Julia E. Altman, et al.
Pubblicazione: (2024)

Targeting neutrophils: Mechanism and advances in cancer therapy
di: Shuaixi Yang, et al.
Pubblicazione: (2024)

Targeting autophagy: A promising approach for the treatment of breast cancer brain metastases
di: Steffan T. Nawrocki, et al.
Pubblicazione: (2024)

Ferroptosis in breast cancer: From adipocyte–immune–iron regulation to therapeutic application
di: Juan Sun, et al.
Pubblicazione: (2026)

Copper in colorectal cancer: From copper‐related mechanisms to clinical cancer therapies
di: Yuhong Wang, et al.
Pubblicazione: (2024)

A plasma‐derived exosomal microRNA signature by small RNA sequencing for early detection of postmenopausal osteoporosis
di: Pan Gao, et al.
Pubblicazione: (2024)

Milk exosomes: Harnessing nature's duality for cancer therapy
di: Asmit Das, et al.
Pubblicazione: (2024)

Engineered cell versus modified exosomes in cancer therapy
di: Rajib Dhar, et al.
Pubblicazione: (2024)

Unlocking oncoembryonic programs for clinical advances in cancer therapy
di: Tosca Dalessi, et al.
Pubblicazione: (2025)

Inhibition of autophagy antagonizes breast cancer brain metastogenesis and augments the anticancer activity of lapatinib
di: Steffan T. Nawrocki, et al.
Pubblicazione: (2024)

CD70: An emerging target for integrated cancer diagnosis and therapy
di: Jiatao Hu, et al.
Pubblicazione: (2025)

Integrated spatial multi‐omics profiling of Fusobacterium nucleatum in breast cancer unveils its role in tumour microenvironment modulation and cancer progression
di: Feng Zhao, et al.
Pubblicazione: (2025)

Effects of microRNA on the growth and targeted therapy response on lung cancer
di: Mengchen Zhu, et al.
Pubblicazione: (2024)

Liquid biopsy—A biomarker‐based revolutionising technique in cancer therapy
di: Subham Sarkar, et al.
Pubblicazione: (2024)

Targeting c‐Myc enhances immunotherapy efficacy in combination with Ras inhibitor in triple‐negative breast cancer
di: Xiaojie Liang, et al.
Pubblicazione: (2025)

Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple‐negative breast cancer patients
di: Chiara Massa, et al.
Pubblicazione: (2024)

Distinct discrepancy in breast cancer organoids recapitulation among molecular subtypes revealed by single‐cell transcriptomes analysis
di: Ziqi Jia, et al.
Pubblicazione: (2024)

Toward precision oncology: An integrative multi‐omics approach for prognosis prediction and inferred immunotherapy responsiveness in breast cancer
di: Houda Bendani, et al.
Pubblicazione: (2026)

NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence
di: Marina Mendiburu‐Eliçabe, et al.
Pubblicazione: (2024)

Predictive circulating biomarkers of the response to anti‐PD‐1 immunotherapy in advanced HER2 negative breast cancer
di: Yuhan Wei, et al.
Pubblicazione: (2025)

RNA methylation‐related inhibitors: Biological basis and therapeutic potential for cancer therapy
di: Huanxiang Chen, et al.
Pubblicazione: (2024)

Integrating oncolytic adenoviruses into combination cancer therapy: Mechanisms, advances and clinical outlook
di: Vlad Iova, et al.
Pubblicazione: (2026)

Current status and future perspectives of multi‐modal bacteria‐based cancer therapies
di: Shuai Fan, et al.
Pubblicazione: (2025)

Diverse potential of chimeric antigen receptor‐engineered cell therapy: Beyond cancer
di: Lvying Wu, et al.
Pubblicazione: (2025)

Immune‐based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer
di: Eudald Felip, et al.
Pubblicazione: (2025)

PCDHGB7 inhibits the progression of triple‐negative breast cancer by suppressing XRCC5/MYC‐mediated ribosome biogenesis
di: Ming Shan, et al.
Pubblicazione: (2025)